Resources

COVID-19 is sparking new demands on Ontario health system leaders – and the surge of need is bigger than traditional communications can carry. There is risk in duplication and gaps in expertise. REAL Resources is our way of curating the disparate information sources reviewed in the development of REAL Notes, and those submitted by others adding to our body of knowledge.

REAL Resources is a common ground for decision makers to find what is working and to see how it works in practice.

Resource Title	Details	Published Ascending Descending
Australian guidelines for clinical care of people with COVID-19 — National COVID-19 Clinical Evidence Taskforce	Type: National Guidance Tags: Patient Care, Symptoms, Treatments	October 27, 2020
Treatment for COVID-19 — Harvard Medical School	Type: Professional Organization Tags: Patient Care, Symptoms, Treatments	October 22, 2020
Remdesivir — CADTH: Canadian Agency for Drugs and Technologies in Health	Type: National Guidance Tags: Patient Care, Symptoms, Treatments	October 21, 2020
Drugs and vaccines for COVID-19: List of authorized clinical trials — Government of Canada	Type: National Guidance Tags: Patient Care, Symptoms, Treatments	October 20, 2020
“Solidarity” clinical trial for COVID-19 treatments — WHO: World Health Organization	Type: International Guidance Tags: Patient Care, Symptoms, Treatments	October 14, 2020
Therapeutic Management of Patients with COVID-19 — National Institutes of Health	Type: National Guidance Tags: Patient Care, Symptoms, Treatments	October 8, 2020
Long-term consequences of COVID-19: research needs — Yelin et al.	Type: Commentary Tags: Clinical Presentation, Long-Covid, Patient Care	September 30, 2020
“Long Covid”: evidence, recommendations and priority research questions — Greenhalgh et al.	Type: Expert Advice to Government Tags: Clinical Presentation, Long-Covid, Patient Care	September 22, 2020
As Their Numbers Grow, COVID-19 “Long Haulers” Stump Experts — Rita Rubin	Type: News Item Tags: Clinical Presentation, Long-Covid, Patient Care	September 22, 2020
The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19 — Harbuwono et al.	Type: Single Study Tags: Influenza, Patient Care, Symptoms, Treatments	September 21, 2020

Resources

Filters Close

Australian guidelines for clinical care of people with COVID-19 — National COVID-19 Clinical Evidence Taskforce

Treatment for COVID-19 — Harvard Medical School

Remdesivir — CADTH: Canadian Agency for Drugs and Technologies in Health

Drugs and vaccines for COVID-19: List of authorized clinical trials — Government of Canada

“Solidarity” clinical trial for COVID-19 treatments — WHO: World Health Organization

Therapeutic Management of Patients with COVID-19 — National Institutes of Health

Long-term consequences of COVID-19: research needs — Yelin et al.

“Long Covid”: evidence, recommendations and priority research questions — Greenhalgh et al.

As Their Numbers Grow, COVID-19 “Long Haulers” Stump Experts — Rita Rubin

The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19 — Harbuwono et al.

Filters